By Adria Calatayud 
 

AstraZeneca PLC (AZN.LN) said Friday that the EU drug regulator's Committee for Medicinal Products for Human Use has recommended marketing authorization for Bevespi Aerosphere, an inhaler for treatment of chronic obstructive pulmonary disease.

The recommendation from the European Medicines Agency committee is based on the company's phase 3 pinnacle program, which demonstrated the efficacy and safety of the inhaler, the pharmaceutical company said.

Bevespi Aerosphere is approved in the U.S., Canada and Australia as a dual bronchodilator for the long-term maintenance treatment of chronic obstructive pulmonary disease, AstraZeneca said.

Shares at 1216 GMT were up 0.8% at 5,927 pence.

 

Write to Adria Calatayud at adria.calatayudvaello@dowjones.com

 

(END) Dow Jones Newswires

October 19, 2018 08:36 ET (12:36 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more AstraZeneca Charts.